Skip to main content
Universal Drugstore logo

Anoro Ellipta vs Trelegy Ellipta for COPD

When managing COPD (chronic obstructive pulmonary disease), choosing the right inhaler medication can significantly impact your quality of life and long-term health outcomes. Two commonly prescribed options are Anoro Ellipta (umeclidinium/vilanterol) and Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol). Both are once-daily inhalers from the same manufacturer, but they work differently and are prescribed for different stages of COPD management.

Shop Medications

,

In This Article

What is Anoro Ellipta?

Anoro Ellipta contains two active ingredients that work together to keep your airways open and make breathing easier. The medication combines umeclidinium, which is a LAMA (long-acting muscarinic antagonist), with vilanterol, a LABA (long-acting beta agonist).

This dual therapy approach relaxes the muscles around your airways and keeps them open for 24 hours with just one daily dose. Anoro is prescribed for long-term, once-daily maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and emphysema.

It’s important to understand that Anoro is not a rescue inhaler. You cannot use it for sudden breathing problems or COPD flare-ups that require immediate relief.

What is Trelegy Ellipta?

Trelegy Ellipta takes COPD treatment one step further by combining three medications in a single inhaler. In addition to the same umeclidinium and vilanterol found in Anoro, Trelegy includes fluticasone furoate, which is an ICS (inhaled corticosteroid).

This triple therapy approach addresses COPD from multiple angles. The LAMA and LABA components work to open airways, while the corticosteroid helps reduce inflammation in the lungs. Trelegy is prescribed for once-daily maintenance treatment in COPD patients who need additional therapy beyond what dual combinations can provide.

Key Differences Between Anoro and Trelegy

The primary difference between these medications is their ingredients and intended use. Anoro contains two bronchodilators that focus solely on opening airways. Trelegy contains these same two bronchodilators plus an inhaled steroid that targets lung inflammation.

The question becomes whether you need that third medication, which depends on your specific COPD symptoms and exacerbation history.

Your doctor will typically start with dual therapy, like Anoro, if you have stable COPD with manageable symptoms. Triple therapy, like Trelegy, is usually reserved for patients who continue to experience frequent exacerbations or worsening symptoms despite dual bronchodilator treatment.

Clinical Effectiveness: What the Research Shows

Large clinical studies have directly compared these medications to understand which works better for different types of COPD patients. The landmark IMPACT study, published in the New England Journal of Medicine, provided clear evidence about the superior effectiveness of triple therapy in certain patient populations.

In this major clinical trial, researchers found that once-daily Trelegy was superior to Anoro in reducing the annual rate of moderate and severe COPD exacerbations. The results showed a 25% reduction in exacerbation rates when comparing Trelegy to Anoro.

Perhaps more importantly, the study demonstrated a 34% reduction in COPD hospitalizations for patients taking Trelegy compared to those taking Anoro. This translates to fewer severe exacerbations that require emergency medical care.

The research also showed a significant reduction in all-cause mortality risk, with patients taking Trelegy having a 42.1% lower risk compared to those taking Anoro. Additionally, patients experienced improved lung function and better health-related quality of life scores.

Real-World Patient Experiences

Clinical trial results tell only part of the story. Real-world studies looking at patient experiences provide additional insights into how these medications perform in everyday use.

Research examining patient-reported outcomes found that Trelegy use was associated with fewer COPD exacerbations and fewer hospitalizations compared to single or dual inhaler regimens like Anoro. However, the same study noted that some patients experienced different symptom burdens with Trelegy, highlighting that individual responses can vary.

This reinforces an important principle in COPD management: what works best varies from person to person. While the clinical evidence strongly favors triple therapy for reducing exacerbations and hospitalizations, some patients may experience trade-offs in terms of side effects or daily symptom management.

Side Effects and Safety Considerations

Common Side Effects

Both Anoro and Trelegy share many common side effects since they contain the same two bronchodilators. These frequently reported side effects include:

  • Sore throat: Often, the most common complaint with both medications
  • Cough: May occur as your lungs adjust to the medication
  • Diarrhea: Usually mild and temporary
  • Vomiting or nausea: More common when first starting treatment
  • Taste changes: Some patients notice a different taste in their mouth

Because Trelegy contains an inhaled corticosteroid, it carries additional risks not present with Anoro. These include:

  • Oral thrush: A fungal infection in the mouth that can be prevented by rinsing after use
  • Increased infection risk: The steroid component can make you slightly more susceptible to respiratory infections
  • Voice changes: Some patients experience hoarseness

Serious but Rare Side Effects

Both medications can cause serious side effects, though these occur in less than 1% of patients. These include severe allergic reactions, heart rhythm problems, and worsening of narrow-angle glaucoma or enlarged prostate symptoms.

Trelegy carries additional rare risks related to its corticosteroid component, including pneumonia (reported in clinical trials), bone density changes with long-term use, and effects on blood sugar in diabetic patients.

Who Should Use Which Medication?

The choice between Anoro and Trelegy isn’t arbitrary. Medical guidelines and clinical evidence provide clear direction on when each medication is most appropriate.

Anoro is typically prescribed for patients with stable COPD who need maintenance bronchodilator therapy. This dual therapy approach works well for many patients and avoids the potential side effects that come with inhaled steroids.

Trelegy becomes the better choice for patients who continue to have exacerbations despite dual bronchodilator treatment, particularly those with elevated blood eosinophil counts or a history of frequent flare-ups. The addition of the inhaled corticosteroid provides extra protection against inflammation-driven exacerbations.

Your doctor will consider several factors when choosing between these medications, including your exacerbation history, current symptoms, blood eosinophil levels, and how well you’ve responded to previous treatments.

Proper Usage and Important Reminders

Both Anoro and Trelegy are once-daily maintenance medications taken at the same time each day. Neither should be used as a rescue inhaler for sudden breathing problems. You should always keep a separate quick-relief inhaler available for acute symptoms.

If you’re prescribed Trelegy, rinse your mouth with water and spit it out after each use. This simple step significantly reduces your risk of developing oral thrush, a common side effect of inhaled corticosteroids.

Both medications come in the same type of dry powder inhaler device. Make sure you understand how to use it properly, as incorrect technique can reduce the medication’s effectiveness. Your pharmacist or respiratory therapist can demonstrate the proper technique.

Cost Considerations

Both Anoro and Trelegy can be expensive medications, especially for patients without adequate insurance coverage. The cost difference between them is usually modest, so price alone shouldn’t drive your treatment decision.

If you’re concerned about medication costs, discuss your options with your healthcare provider. For patients looking for more affordable access to these medications, cash-pay options through services like Universal Drugstore may provide significant savings compared to traditional retail pharmacy prices.

Some patients qualify for manufacturer assistance programs that can reduce out-of-pocket costs. Your doctor’s office or pharmacist can help you explore these options.

Making the Right Choice for Your COPD

The decision between Anoro and Trelegy should always be made in partnership with your healthcare provider. While the clinical evidence strongly supports triple therapy like Trelegy for patients with frequent exacerbations, dual therapy like Anoro remains an excellent choice for many patients with stable disease.

Your treatment may also change over time. Some patients start with Anoro and later switch to Trelegy if their symptoms worsen, or they begin experiencing more frequent exacerbations. Others may step down from triple to dual therapy if their condition stabilizes.

Remember that COPD management extends beyond medication choice. Regular exercise, smoking cessation, vaccinations, and pulmonary rehabilitation all play crucial roles in maintaining your health and quality of life.

Work closely with your healthcare team to monitor your symptoms, track exacerbations, and adjust your treatment plan as needed. The goal is finding the right balance of effective symptom control with minimal side effects, helping you maintain the best possible quality of life while managing your COPD.

References

Related Conditions